The DOI matches its Crossref record; 300 of the 300 references it cites were found in a registry or an index.
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
Open accessAbstract
Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and produce aggressive malignancies that causes millions of deaths every year. With the new understanding of the molecular mechanism(s) of disease progression, our knowledge about the disease is snowballing, leading to the evolution of many new therapeutic regimes and their successive trials. In the past few decades, various combinations of therapies have been proposed and are presently employed in the treatment of diverse cancers. Targeted drug therapy, immunotherapy, and personalized medicines are now largely being employed, which were not common a few years back. The field of cancer discoveries and therapeutics are evolving fast as cancer type-specific biomarkers are progressively being identified and several types of cancers are nowadays undergoing systematic therapies, extending patients' disease-free survival thereafter. Although growing evidence shows that a systematic and targeted approach could be the future of cancer medicine, chemotherapy remains a largely opted therapeutic option despite its known side effects on the patient's physical and psychological health. Chemotherapeutic agents/pharmaceuticals served a great purpose over the past few decades and have remained the frontline choice for advanced-stage malignancies where surgery and/or radiation therapy cannot be prescribed due to specific reasons. The present report succinctly reviews the existing and contemporary advancements in chemotherapy and assesses the status of the enrolled drugs/pharmaceuticals; it also comprehensively discusses the emerging role of specific/targeted therapeutic strategies that are presently being employed to achieve better clinical success/survival rate in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhou, L., Fan, R., Tong, A., Li, X., Gao, X., Lan, M., Zhang, X., You, C., & Guo, G. F. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s89066 · Cited by 107
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617 · cited 1×
“The immunotherapy drugs are given alone or in combination with chemotherapy drugs to achieve better clinical outcomes.(229) Prophylactic and therapeutic vaccines have been developed to help patients’ immune systems towards learning to tackle the transformed cells.”
BackgroundTherapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Pommier, Y., Leo, E., Zhang, H., & Marchand, C. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.04.012 · Cited by 1,829
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“An oral BRAF inhibitor, namely vemurafenib has been shown to possess a greater affinity for the mutant BRAF than the wildtype BRAF, and therefore was recommended to the patients carrying the above mutation in the tumors.(196) Several potential targets for novel drugs have been identified using high-throughput screenin…”
BackgroundArtificial intelligence in digital pathology — new tools for diagnosis and precision oncology
Bera, K., Schalper, K. A., Rimm, D. L., Velcheti, V., & Madabhushi, A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0252-y · Cited by 1,698
Cancer-related fatigue—mechanisms, risk factors, and treatments
Bower, J. E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.127 · Cited by 1,666
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
How Taxol/paclitaxel kills cancer cells
Weaver, B. A. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0916 · Cited by 1,547
Cancer—Principles & Practice of Oncology
Rhoads, J. E. (1983) · PubMed Central · Cited by 1,466
Benson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430
The antimicrobial peptides and their potential clinical applications.
Lei, J., Sun, L., Huang, S., Zhu, C., Li, P., He, J., Mackey, V., Coy, D. H., & He, Q. (2019) · PubMed · Cited by 1,429
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,296
Sawyers, C. (2004) · Nature · doi:10.1038/nature03095 · Cited by 1,165
The Principles of Engineering Immune Cells to Treat Cancer
Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,080
Natural killer cells and other innate lymphoid cells in cancer
Chiossone, L., Dumas, P.-Y., Vienne, M., & Vivier, E. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0061-z · Cited by 1,007
Emerging connectivity of programmed cell death pathways and its physiological implications
Bedoui, S., Herold, M. J., & Strasser, A. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0270-8 · Cited by 979
Etoposide: four decades of development of a topoisomerase II inhibitor
Hande, K. R. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00228-7 · Cited by 949
Turning Cold into Hot: Firing up the Tumor Microenvironment
Duan, Q., Zhang, H., Zheng, J., & Zhang, L. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.022 · Cited by 934
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Falzone, L., Salomone, S., & Libra, M. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01300 · Cited by 908
Anand, U., Jacobo-Herrera, N., Altemimi, A., & Lakhssassi, N. (2019) · Metabolites · doi:10.3390/metabo9110258 · Cited by 867
Self-citationCurigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., Criscitiello, C., Goldhirsch, A., Cipolla, C., & Roila, F. (2012) · Annals of Oncology · doi:10.1093/annonc/mds293 · Cited by 865
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Cellular pharmacology of gemcitabine
Mini, E., Nobili, S., Caciagli, B., Landini, I., & Mazzei, T. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj941 · Cited by 842
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond
Holderfield, M., Deuker, M. M., McCormick, F., & McMahon, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3760 · Cited by 833
Advances and challenges in targeting FGFR signalling in cancer
Babina, I. S., & Turner, N. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.8 · Cited by 799
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Metabolic Reprogramming: the Emerging Concept and Associated Therapeutic Strategies
Yoshida, G. J. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0221-y · Cited by 716
Antibody–drug conjugates: targeted drug delivery for cancer
Alley, S. C., Okeley, N. M., & Senter, P. D. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.06.170 · Cited by 656
Palmer, A. C., & Sorger, P. K. (2017) · Cell · doi:10.1016/j.cell.2017.11.009 · Cited by 642
Nicholson, L. B. (2016) · Essays in Biochemistry · doi:10.1042/ebc20160017 · Cited by 623
Progress in research on paclitaxel and tumor immunotherapy
Zhu, L., & Chen, L. (2019) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-019-0164-y · Cited by 616
Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors
Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603
The adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Mitomycin C: small, fast and deadly (but very selective)
Tomasz, M. (1995) · Chemistry & Biology · doi:10.1016/1074-5521(95)90120-5 · Cited by 581
Precision medicine for cancer with next-generation functional diagnostics
Friedman, A. A., Letai, A., Fisher, D. E., & Flaherty, K. T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4015 · Cited by 570
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
Jäger, U., Barcellini, W., Broome, C. M., Gertz, M. A., Hill, A., Hill, Q. A., Jilma, B., Kuter, D. J., Michel, M., Montillo, M., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2019.100648 · Cited by 565
Actinomycin and DNA transcription.
Sobell, H. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.16.5328 · Cited by 561
Chua, T. C., Yan, T. D., Saxena, A., & Morris, D. L. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181a45d86 · Cited by 532
Basic and Clinical Pharmacology
Holley, F. (1984) · Anesthesiology · doi:10.1097/00000542-198403000-00038 · Cited by 488
Tan, C., Tasaka, H., Yu, K.-P., Murphy, M. L., & Karnofsky, D. A. (1967) · Cancer · doi:10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k · Cited by 486
Formation and Repair of Interstrand Cross-Links in DNA
Noll, D. M., Mason, T. M., & Miller, P. S. (2006) · Chemical Reviews · doi:10.1021/cr040478b · Cited by 484
Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P., Giaccone, G., Schaefer, B., Wanders, J., & Verweij, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2090 · Cited by 480
Makovec, T. (2019) · Radiology and Oncology · doi:10.2478/raon-2019-0018 · Cited by 480
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Matei, D., Filiaci, V., Randall, M. E., Mutch, D., Steinhoff, M. M., DiSilvestro, P. A., Moxley, K. M., Kim, Y. M., Powell, M. A., O’Malley, D. M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813181 · Cited by 477
Anticancer Activity of Natural Compounds from Plant and Marine Environment
Lichota, A., & Gwozdzinski, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113533 · Cited by 473
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
Next-generation sequencing for cancer diagnostics: a practical perspective.
Meldrum, C. J., Doyle, M., & Tothill, R. W. (2011) · Europe PMC (PubMed Central) · Cited by 443
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
Fornari, F. A., Randolph, J. K., Yalowich, J. C., Ritke, M. K., & Gewirtz, D. A. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10149-1 · Cited by 436
Patel, J. D., Krilov, L., Adams, S., Aghajanian, C., Basch, E., Brose, M. S., Carroll, W. L., de Lima, M., Gilbert, M. R., Kris, M. G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7076 · Cited by 434
Natural compounds as potential adjuvants to cancer therapy: Preclinical evidence
Lin, S., Chang, C., Hsu, C., Tsai, M., Cheng, H., Leong, M. K., Sung, P., Chen, J., & Weng, C. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14816 · Cited by 425
Mechanisms of action of methotrexate
Genestier, L., Paillot, R., Quemeneur, L., Izeradjene, K., & Revillard, J.-P. (2000) · Immunopharmacology · doi:10.1016/s0162-3109(00)00189-2 · Cited by 424
de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0644-7 · Cited by 421
5-Fluorouracil: Forty-Plus and Still Ticking. A Review of its Preclinical and Clinical Development
Grem, J. L. (2000) · Investigational New Drugs · doi:10.1023/a:1006416410198 · Cited by 417
Cytarabine Dose for Acute Myeloid Leukemia
Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Biemond, B. J., Gratwohl, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010222 · Cited by 407
Dieci, M. V., Arnedos, M., Andre, F., & Soria, J. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0362 · Cited by 406
Dias‐Santagata, D., Akhavanfard, S., David, S. S., Vernovsky, K., Kuhlmann, G., Boisvert, S. L., Stubbs, H., McDermott, U., Settleman, J., Kwak, E. L., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000070 · Cited by 396
Eckardt, J. R., von Pawel, J., Pujol, J.-L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Preston, A. J., Dane, G., & Ross, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3998 · Cited by 393
Peptides with Dual Antimicrobial and Anticancer Activities
Felício, M. R., Silva, O. N., Gonçalves, S., Santos, N. C., & Franco, O. L. (2017) · Frontiers in Chemistry · doi:10.3389/fchem.2017.00005 · Cited by 393
Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities
Tornesello, A. L., Borrelli, A., Buonaguro, L., Buonaguro, F. M., & Tornesello, M. L. (2020) · Molecules · doi:10.3390/molecules25122850 · Cited by 383
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Doxorubicin: nanotechnological overviews from bench to bedside
Cagel, M., Grotz, E., Bernabeu, E., Moretton, M. A., & Chiappetta, D. A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.005 · Cited by 362
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Hollingshead, L. M., & Faulds, D. (1991) · Drugs · doi:10.2165/00003495-199142040-00010 · Cited by 345
Zhu, K., Dunner, K., & McConkey, D. J. (2010) · Oncogene · doi:10.1038/onc.2009.343 · Cited by 338
Vinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead
Martino, E., Casamassima, G., Castiglione, S., Cellupica, E., Pantalone, S., Papagni, F., Rui, M., Siciliano, A. M., & Collina, S. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.06.044 · Cited by 337
Krauss, A. C., Gao, X., Li, L., Manning, M. L., Patel, P., Fu, W., Janoria, K. G., Gieser, G., Bateman, D. A., Przepiorka, D., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2990 · Cited by 332
Camptothecin and taxol: Discovery to clinic
Wall, M. E. (1998) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199809)18:5<299::aid-med2>3.0.co;2-o · Cited by 330
Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies
Ho, G. Y., Woodward, N., & Coward, J. I. G. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.014 · Cited by 325
The role of reactive oxygen species and metabolism on cancer cells and their microenvironment
Costa, A., Scholer-Dahirel, A., & Mechta-Grigoriou, F. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.007 · Cited by 324
A systematic analysis of FDA-approved anticancer drugs
Sun, J., Wei, Q., Zhou, Y., Wang, J., Liu, Q., & Xu, H. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0464-7 · Cited by 322
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
Ferrucci, P. F., Pala, L., Conforti, F., & Cocorocchio, E. (2021) · Cancers · doi:10.3390/cancers13061383 · Cited by 317
Li, F., Jiang, T., Li, Q., & Ling, X. (2017) · PubMed · Cited by 315
Sambi, M., Bagheri, L., & Szewczuk, M. R. (2019) · Journal of Oncology · doi:10.1155/2019/4508794 · Cited by 313
Paul, S., Chakraborty, S., Anand, U., Dey, S., Nandy, S., Ghorai, M., Saha, S. C., Patil, M. T., Kandimalla, R., Proćków, J., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112175 · Cited by 306 · cited 1×
“New trends are evolving in the drug discovery paradigm that includes designing new derivatives of old drugs with high efficacy and lower toxicities.(269,270) Several natural compounds isolated from microbial, plants, or natural sources were suggested to hold enormous potential to target stress response pathways by mou…”
BackgroundSelf-citationCAR T cells: Continuation in a revolution of immunotherapy
Singh, A. K., & McGuirk, J. P. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30823-x · Cited by 303
Microtubule destabilising agents: far more than just antimitotic anticancer drugs
Bates, D., & Eastman, A. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13126 · Cited by 298
Zhou, Q., Jin, J.-F., Zhu, L.-L., Chen, M., Xu, H.-M., Wang, H.-F., Feng, X.-Q., & Zhu, X.-P. (2015) · Patient Preference and Adherence · doi:10.2147/ppa.s87271 · Cited by 296
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
DNA Damage Induced by Alkylating Agents and Repair Pathways
Kondo, N., Takahashi, A., Ono, K., & Ohnishi, T. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/543531 · Cited by 292
The immune system in cancer metastasis: friend or foe?
Janssen, L. M. E., Ramsay, E. E., Logsdon, C. D., & Overwijk, W. W. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0283-9 · Cited by 292
Managing thrombocytopenia associated with cancer chemotherapy.
Kuter, D. J. (2015) · PubMed · Cited by 290
Antimicrobial peptides: new hope in the war against multidrug resistance
Mwangi, J., Hao, X., Lai, R., & Zhang, Z.-Y. (2019) · Zool. Res. · doi:10.24272/j.issn.2095-8137.2019.062 · Cited by 289
Antibody-Based Immunotherapy of Cancer
Weiner, L. M., Murray, J. C., & Shuptrine, C. W. (2012) · Cell · doi:10.1016/j.cell.2012.02.034 · Cited by 284
Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer
Hughes, P. E., Caenepeel, S., & Wu, L. C. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.010 · Cited by 282
Exploring phytochemicals for combating antibiotic resistance in microbial pathogens
Khare, T., Anand, U., Dey, A., Assaraf, Y. G., Chen, Z.-S., Liu, Z., & Kumar, V. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720726 · Cited by 281 · cited 1×
“4).(204,209,210) Cathelicidins are members of the antimicrobial peptide family found in granules of vertebrate neutrophils.”
BackgroundCombining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 280
Arsenic trioxide — An old drug rediscovered
Emadi, A., & Gore, S. D. (2010) · Blood Reviews · doi:10.1016/j.blre.2010.04.001 · Cited by 279
Stähelin, H., & von Wartburg, A. (1991) · PubMed · Cited by 278
Postma, T. J., Vermorken, J. B., Liefting, A. J. M., Pinedo, H. M., & Heimans, J. J. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059220 · Cited by 271
Targeted drug delivery for cancer therapy: the other side of antibodies
Firer, M. A., & Gellerman, G. (2012) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-5-70 · Cited by 269
Azathioprine: old drug, new actions
Maltzman, J. S., & Koretzky, G. A. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18384 · Cited by 268
Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond
Vaidyanathan, R., Soon, R. H., Zhang, P., Jiang, K., & Lim, C. T. (2018) · Lab on a Chip · doi:10.1039/c8lc00684a · Cited by 259
Cathelicidins: Immunomodulatory Antimicrobials
Van Harten, R. M., Van Woudenbergh, E., Van Dijk, A., & Haagsman, H. P. (2018) · Vaccines · doi:10.3390/vaccines6030063 · Cited by 258
Discovery and development of clofarabine: a nucleoside analogue for treating cancer
Bonate, P. L., Arthaud, L., Cantrell, W. R., Stephenson, K., Secrist, J. A., & Weitman, S. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2055 · Cited by 257
Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer
Hasima, N., & Ozpolat, B. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.467 · Cited by 257
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Self-citationChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments
McQuade, R. M., Stojanovska, V., Abalo, R., Bornstein, J. C., & Nurgali, K. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00414 · Cited by 252
Graham, J., Muhsin, M., & Kirkpatrick, P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1287 · Cited by 251
The mechanism of the bleomycin-induced cleavage of DNA
William Lown, J., & Sim, S.-K. (1977) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(77)80099-5 · Cited by 248
Kalyanaraman, B. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.018 · Cited by 246
Biophysics of tumor microenvironment and cancer metastasis – a mini review
Emon, B., Bauer, J., Jain, Y., Jung, B., & Saif, T. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.07.003 · Cited by 245
Targeting Oncogenic BRAF: Past, Present, and Future
Zaman, A., Wu, W., & Bivona, T. G. (2019) · Cancers · doi:10.3390/cancers11081197 · Cited by 245
Nanotechnology in Cancer Drug Delivery and Selective Targeting
Sutradhar, K. B., & Amin, M. L. (2014) · ISRN Nanotechnology · doi:10.1155/2014/939378 · Cited by 241
Abolmaali, S. S., Tamaddon, A. M., & Dinarvand, R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2062-0 · Cited by 240
Sexual dysfunction and infertility as late effects of cancer treatment
Schover, L. R., van der Kaaij, M., van Dorst, E., Creutzberg, C., Huyghe, E., & Kiserud, C. E. (2014) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2014.03.004 · Cited by 234
Cancer nanomedicine: is targeting our target?
Lammers, T., Kiessling, F., Ashford, M., Hennink, W., Crommelin, D., & Storm, G. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.69 · Cited by 233
DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents
Raimondi, M. V., Randazzo, O., La Franca, M., Barone, G., Vignoni, E., Rossi, D., & Collina, S. (2019) · Molecules · doi:10.3390/molecules24061140 · Cited by 233
Molecular targeted therapy of cancer: The progress and future prospect
Ke, X., & Shen, L. (2017) · Frontiers in Laboratory Medicine · doi:10.1016/j.flm.2017.06.001 · Cited by 231
Advances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Coccia, M. (2020) · Technology in Society · doi:10.1016/j.techsoc.2019.101198 · Cited by 230
Human Tumor Antigens and Cancer Immunotherapy
Vigneron, N. (2015) · BioMed Research International · doi:10.1155/2015/948501 · Cited by 228
Antimicrobial Peptides and Nanotechnology, Recent Advances and Challenges
Biswaro, L. S., da Costa Sousa, M. G., Rezende, T. M. B., Dias, S. C., & Franco, O. L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00855 · Cited by 227
Gemcitabine versus Modified Gemcitabine: A Review of Several Promising Chemical Modifications
Moysan, E., Bastiat, G., & Benoit, J.-P. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300370t · Cited by 225
DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
Bodley, A. L., Liu, L. F., Israel, M., Seshadri, R., Koseki, Y., Giuliani, F. C., Kirschenbaum, S., Silber, R., & Potmĕsil, M. (1989) · PubMed · Cited by 225
Konstantinopoulos, P. A., Cheng, S.-C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L. R., Crispens, M. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30180-7 · Cited by 225
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
D’Incalci, M., Badri, N., Galmarini, C. M., & Allavena, P. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.149 · Cited by 218
Mechanism of action of mitoxantrone
Fox, E. J. (2004) · Neurology · doi:10.1212/wnl.63.12_suppl_6.s15 · Cited by 214
Wang, Y., Probin, V., & Zhou, D. (2006) · Current Cancer Therapy Reviews · doi:10.2174/157339406777934717 · Cited by 213
Karahoca, M., & Momparler, R. L. (2013) · Clinical Epigenetics · doi:10.1186/1868-7083-5-3 · Cited by 213
Principles of adoptive T cell therapy in cancer
Met, Ö., Jensen, K. M., Chamberlain, C. A., Donia, M., & Svane, I. M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 213
Future cancer research priorities in the USA: a Lancet Oncology Commission
Jaffee, E. M., Dang, C. V., Agus, D. B., Alexander, B. M., Anderson, K. C., Ashworth, A., Barker, A. D., Bastani, R., Bhatia, S., Bluestone, J. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30698-8 · Cited by 208
Gilbert, S., Oliphant, C., Hassan, S., Peille, A., Bronsert, P., Falzoni, S., Di Virgilio, F., McNulty, S., & Lara, R. (2019) · Oncogene · doi:10.1038/s41388-018-0426-6 · Cited by 197
Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery
Salazar, M. C., Rosen, J. E., Wang, Z., Arnold, B. N., Thomas, D. C., Herbst, R. S., Kim, A. W., Detterbeck, F. C., Blasberg, J. D., & Boffa, D. J. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5829 · Cited by 193
Advances in Receptor‐Mediated, Tumor‐Targeted Drug Delivery
Large, D. E., Soucy, J. R., Hebert, J., & Auguste, D. T. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800091 · Cited by 190
Novel delivery approaches for cancer therapeutics
Mitra, A. K., Agrahari, V., Mandal, A., Cholkar, K., Natarajan, C., Shah, S., Joseph, M., Trinh, H. M., Vaishya, R., Yang, X., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.067 · Cited by 183
Clinical Pharmacokinetics of Topotecan
Herben, V. M. M., ten Bokkel Huinink, W. W., & Beijnen, J. H. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199631020-00001 · Cited by 180
FDA Drug Approval Summaries: Oxaliplatin
Ibrahim, A., Hirschfeld, S., Cohen, M. H., Griebel, D. J., Williams, G. A., & Pazdur, R. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-8 · Cited by 180
Emerging Cytotoxic Alkaloids in the Battle against Cancer: Overview of Molecular Mechanisms
Habli, Z., Toumieh, G., Fatfat, M., Rahal, O., & Gali-Muhtasib, H. (2017) · Molecules · doi:10.3390/molecules22020250 · Cited by 178
Adenosine and Inflammation: Here, There and Everywhere
Pasquini, S., Contri, C., Borea, P. A., Vincenzi, F., & Varani, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147685 · Cited by 178
Nanodelivery Strategies in Cancer Chemotherapy: Biological Rationale and Pharmaceutical Perspectives
Mattheolabakis, G., Rigas, B., & Constantinides, P. P. (2012) · Nanomedicine · doi:10.2217/nnm.12.128 · Cited by 177
Revisiting the hallmarks of cancer: The role of hyaluronan
Caon, I., Bartolini, B., Parnigoni, A., Caravà, E., Moretto, P., Viola, M., Karousou, E., Vigetti, D., & Passi, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.007 · Cited by 176
Mechanisms of action of methotrexate.
Chan, E. S. L., & Cronstein, B. N. (2013) · PubMed · Cited by 174
Piktel, E., Niemirowicz, K., Wątek, M., Wollny, T., Deptuła, P., & Bucki, R. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0193-x · Cited by 171
Advances in nano-delivery systems for doxorubicin: an updated insight
Kanwal, U., Bukhari, N. I., Ovais, M., Abass, N., Hussain, K., & Raza, A. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1380655 · Cited by 171
Markham, M. J., Wachter, K., Agarwal, N., Bertagnolli, M. M., Chang, S. M., Dale, W., Diefenbach, C. S. M., Rodriguez-Galindo, C., George, D. J., Gilligan, T. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03141 · Cited by 171
Buzdar, A. U., Suman, V. J., Meric-Bernstam, F., Leitch, A. M., Ellis, M. J., Boughey, J. C., Unzeitig, G., Royce, M., McCall, L. M., Ewer, M. S., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70502-3 · Cited by 170
Cytarabine and daunorubicin for the treatment of acute myeloid leukemia
Murphy, T., & Yee, K. W. L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1391216 · Cited by 169
LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
Fabisiak, A., Murawska, N., & Fichna, J. (2016) · Pharmacological Reports · doi:10.1016/j.pharep.2016.03.015 · Cited by 165
Mitra, S., Anand, U., Jha, N. K., Shekhawat, M. S., Saha, S. C., Nongdam, P., Rengasamy, K. R. R., Proćków, J., & Dey, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772418 · Cited by 165
Self-citationVivek, R., Thangam, R., NipunBabu, V., Rejeeth, C., Sivasubramanian, S., Gunasekaran, P., Muthuchelian, K., & Kannan, S. (2014) · ACS Applied Materials & Interfaces · doi:10.1021/am406012g · Cited by 163
Adapt and conquer: Metabolic flexibility in cancer growth, invasion and evasion
Kreuzaler, P., Panina, Y., Segal, J., & Yuneva, M. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2019.08.021 · Cited by 163
Anand, U., Carpena, M., Kowalska‐Góralska, M., García-Pérez, P., Sunita, K., Bontempi, E., Dey, A., Prieto, M. A., Proćków, J., & Simal‐Gándara, J. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.153472 · Cited by 163
Self-citationPharmacology and Mechanism of Action of Pemetrexed
Adjei, A. A. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.s.003 · Cited by 161
Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma
Yarchoan, M. M., Agarwal, P., Villanueva, A., Rao, S., Dawson, L. A., Karasic, T. B., Llovet, J. M., Finn, R. S., Groopman, J. D., El‐Serag, H. B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0803 · Cited by 161
Anand, U., Tudu, C. K., Nandy, S., Sunita, K., Tripathi, V., Loake, G. J., Dey, A., & Proćków, J. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114744 · Cited by 161
Self-citationGasparini, G., Caffo, O., Barni, S., Frontini, L., Testolin, A., Guglielmi, R. B., & Ambrosini, G. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2094 · Cited by 160
Moudi, M., Go, R., Yien, C. Y. S., et al. (2013) · PubMed · Cited by 159
MGMT hypermethylation: A prognostic foe, a predictive friend
Jacinto, F. V., & Esteller, M. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.013 · Cited by 158
Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents
Patel, S. V. (2015) · Journal of Dietary Supplements · doi:10.3109/19390211.2015.1008614 · Cited by 157
Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37
Wang, G., Narayana, J. L., Mishra, B., Zhang, Y., Wang, F., Wang, C., Zarena, D., Lushnikova, T., & Wang, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-3588-4_12 · Cited by 157
Clinical Applications of Antimicrobial Peptides (AMPs): Where do we Stand Now?
Divyashree, M., Mani, M. K., Reddy, D., Kumavath, R., Ghosh, P., Azevedo, V., & Barh, D. (2019) · Protein and Peptide Letters · doi:10.2174/0929866526666190925152957 · Cited by 155
Hemorrhagic cystitis: A challenge to the urologist
Dorairajan, L. N., Manikandan, R., & Kumar, S. (2010) · Indian Journal of Urology · doi:10.4103/0970-1591.65380 · Cited by 154
Leu, J. I.-J., Pimkina, J. S., Pandey, P., Murphy, M. E., & George, D. L. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0019 · Cited by 154
Schmiegelow, K., Al-Modhwahi, I., Andersen, M. K., Behrendtz, M., Forestier, E., Hasle, H., Heyman, M. M., Kristinsson, J., Nersting, J., Nygaard, R., et al. (2009) · Blood · doi:10.1182/blood-2008-11-187880 · Cited by 152
Selimović, D., Porzig, B. B. O. W., El‐Khattouti, A., Badura, H. E., Ahmad, M., Ghanjati, F., Santourlidis, S., Haïkel, Y., & Hassan, M. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.10.004 · Cited by 146
Roudi, R., Syn, N. L., & Roudbary, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01320 · Cited by 139
Lambie, D. G., & Johnson, R. H. (1985) · Drugs · doi:10.2165/00003495-198530020-00003 · Cited by 138
Physicians' Cancer Chemotherapy Drug Manual 2001
Manzullo, E. F., & Anderson, R. W. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-4-200202190-00017 · Cited by 137
Liver Injury Induced by Anticancer Chemotherapy and Radiation Therapy
Maor, ., & Malnick, S. D. H. (2013) · International Journal of Hepatology · doi:10.1155/2013/815105 · Cited by 137
Hydroxyurea: a key player in cancer chemotherapy
Madaan, K., Kaushik, D., & Verma, T. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.175 · Cited by 133
Medicinal Chemistry of Anticancer Drugs
Avendaño, C., & Menéndez, J. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-444-52824-7.x0001-7 · Cited by 131
Fanale, D., Bronte, G., Passiglia, F., Calò, V., Castiglia, M., Piazza, F. D., Barraco, N., Cangemi, A. G., Catarella, M. T., Insalaco, L., et al. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/690916 · Cited by 130
Mechanisms of anti-cancer action and pharmacology of clofarabine
Zhenchuk, A., Lotfi, K., Juliusson, G., & Albertioni, F. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.06.094 · Cited by 129
Beyond BRAF: where next for melanoma therapy?
Fedorenko, I. V., Gibney, G. T., Sondak, V. K., & Smalley, K. S. M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.476 · Cited by 128
Antimicrobial peptides: Role in human disease and potential as immunotherapies
de la Fuente‐Núñez, C., Silva, O. N., Lu, T. K., & Franco, O. L. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.04.002 · Cited by 128
Highlights in Resistance Mechanism Pathways for Combination Therapy
Delou, J. M. D. A., Souza, A. S. O., Souza, L. C. D. M. E., & Borges, H. L. (2019) · Cells · doi:10.3390/cells8091013 · Cited by 126
Ocular toxicity and cancer chemotherapy: A review
Al‐Tweigeri, T., Nabholtz, J., & Mackey, J. R. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961001)78:7<1359::aid-cncr1>3.0.co;2-g · Cited by 125
Mahner, S., zu Eulenburg, C., Staehle, A., Wegscheider, K., Reuß, A., Pujade-Lauraine, É., Harter, P., Ray-Coquard, I., Pfisterer, J., & du Bois, A. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.07.023 · Cited by 124
Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
Kutova, O. M., Guryev, E. L., Соколова, Е. А., Alzeibak, R., & Balalaeva, I. V. (2019) · Cancers · doi:10.3390/cancers11010068 · Cited by 124
Papac, R. J. (2001) · PubMed Central · Cited by 123
The challenges of tumor genetic diversity
Mroz, E. A., & Rocco, J. W. (2016) · Cancer · doi:10.1002/cncr.30430 · Cited by 120
Decitabine/Cedazuridine: First Approval
Dhillon, S. (2020) · Drugs · doi:10.1007/s40265-020-01389-7 · Cited by 120
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117
Unexpected therapeutic effects of cisplatin
Raudenská, M., Balvan, J., Fojtů, M., Gumulec, J., & Masařík, M. (2019) · Metallomics · doi:10.1039/c9mt00049f · Cited by 114
The Treatment of Diseases and the War against Cancer
Cairns, J. (1985) · Scientific American · doi:10.1038/scientificamerican1185-51 · Cited by 113
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review
Engels, F. K., Sparreboom, A., Mathôt, R. A. A., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602698 · Cited by 111
Targeting innate sensing in the tumor microenvironment to improve immunotherapy
Liu, Z., Han, C., & Fu, Y. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0341-y · Cited by 111
Temozolomide: a milestone in neuro-oncology and beyond?
Mutter, N., & Stupp, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.8.1187 · Cited by 109
6-Thioguanine: A Drug With Unrealized Potential for Cancer Therapy
Munshi, P. N., Lubin, M., & Bertino, J. R. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0178 · Cited by 108
Oxaliplatin: a review of approved uses
Stein, A., & Arnold, D. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.643870 · Cited by 107
Ma, M., He, M., Wang, Y., Jiao, X., Zhao, L., Bai, X., Yu, Z., Wu, H., Sun, M., Song, Z. J., et al. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.016 · Cited by 105
Adult T-Cell Leukemia/Lymphoma
Mehta–Shah, N., Ratner, L., & Horwitz, S. M. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.021907 · Cited by 104
Cited by
Cancer drug-tolerant persister cells: from biological questions to clinical opportunities
Russo, M., Chen, M., Mariella, E., Peng, H., Rehman, S. K., Sancho, E., Sogari, A., Toh, T. S., Balaban, N. Q., Batlle, E., et al. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00737-z · Cited by 210
Cellular landscaping of cisplatin resistance in cervical cancer
Bhattacharjee, R., Dey, T., Kumar, L., Kar, S., Sarkar, R., Ghorai, M., Malik, S., Jha, N. K., Vellingiri, B., Kesari, K. K., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113345 · Cited by 93
Self-citationBridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies
Bouquerel, C., Dubrova, A., Hofer, I., Phan, D. T. T., Bernheim, M., Ladaigue, S., Cavaniol, C., Maddalo, D., Cabel, L., Mechta-Grigoriou, F., et al. (2023) · Lab on a Chip · doi:10.1039/d3lc00531c · Cited by 58
Bridging machine learning and peptide design for cancer treatment: a comprehensive review
Rezaee, K., & Eslami, H. (2025) · Artificial Intelligence Review · doi:10.1007/s10462-025-11148-3 · Cited by 34
Histone methyltransferase KMT2A: developmental regulation to oncogenic transformation
Ogino, J., & Dou, Y. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107791 · Cited by 21
Metadata
- Authors
- Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., Dhanjal, J. K., Dewanjee, S., Vallamkondu, J., & Pérez de la Lastra, J. M.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 10
- Issue
- 4
- Pages
- 1367-1401
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W4221040717
- Cited by
- 1,834
- References
- 300
- FWCI
- 95.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.